Abstract
Epilepsy responds to pharmacotherapy in its initial stages. The response of some forms of epilepsy, like the refractory epilepsy, is extremely low. Surgical management of epilepsy is associated with complications, which necessitates the search for novel and modern strategies for the treatment of epilepsy. Neuroprotection and neuronal regeneration are the major targets that must be accomplished by the new strategies. Hematopoietic Stem Cell (HSCs) therapy for epilepsy has shown promising results in pre-clinical studies with marginal clinical effects. This review explores the characteristics, mechanism of action, and clinical significance of HSCs therapy for the treatment of epilepsy.
Keywords: Neuroprotection, neuronal regeneration, antiepileptic property, hematopoietic stem cell treatment, epilepsy, seizure.
CNS & Neurological Disorders - Drug Targets
Title:A Review on Hematopoietic Stem Cell Treatment for Epilepsy
Volume: 20 Issue: 7
Author(s): Mohan Krishna Ghanta, Neha Merchant and Lakkakula V.K.S. Bhaskar*
Affiliation:
- Department of Zoology, Guru Ghasidas University, Bilaspur,India
Keywords: Neuroprotection, neuronal regeneration, antiepileptic property, hematopoietic stem cell treatment, epilepsy, seizure.
Abstract: Epilepsy responds to pharmacotherapy in its initial stages. The response of some forms of epilepsy, like the refractory epilepsy, is extremely low. Surgical management of epilepsy is associated with complications, which necessitates the search for novel and modern strategies for the treatment of epilepsy. Neuroprotection and neuronal regeneration are the major targets that must be accomplished by the new strategies. Hematopoietic Stem Cell (HSCs) therapy for epilepsy has shown promising results in pre-clinical studies with marginal clinical effects. This review explores the characteristics, mechanism of action, and clinical significance of HSCs therapy for the treatment of epilepsy.
Export Options
About this article
Cite this article as:
Ghanta Krishna Mohan, Merchant Neha and Bhaskar V.K.S. Lakkakula *, A Review on Hematopoietic Stem Cell Treatment for Epilepsy, CNS & Neurological Disorders - Drug Targets 2021; 20 (7) . https://dx.doi.org/10.2174/1871527320666210218085816
DOI https://dx.doi.org/10.2174/1871527320666210218085816 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets WNT4 Signaling in Female Gonadal Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents
Current Drug Therapy Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Genes Involved in Hereditary Hearing Impairment
Current Genomics PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Preconception Care for the Type 2 Diabetic Mother: A Review on Current Care Guidelines
Current Women`s Health Reviews Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Variations and Abnormalities of Major Thoracic Vascular Structures
Current Medical Imaging Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery